BiotechTube

Deep neuromuscular block + Moderate neuromuscular block

ApprovedUNKNOWN
3 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuromuscular Block

Conditions

Neuromuscular Block

Trial Timeline

Mar 1, 2016 → Dec 1, 2016

NCT ID
NCT02648503

About Deep neuromuscular block + Moderate neuromuscular block

Deep neuromuscular block + Moderate neuromuscular block is a approved stage product being developed by Merck for Neuromuscular Block. The current trial status is unknown. This product is registered under clinical trial identifier NCT02648503. Target conditions include Neuromuscular Block.

What happened to similar drugs?

14 of 20 similar drugs in Neuromuscular Block were approved

Approved (14) Terminated (2) Active (6)
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
✅neostigmine/glycopyrrolate + sugammadexMerckApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
✅Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
✅Sugammadex + NeostigmineMerckApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02648503ApprovedUNKNOWN

Competing Products

20 competing products in Neuromuscular Block

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
Placebo + Sugammadex + Esmeron®MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
43
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
26
Sugammadex + RocuroniumMerckApproved
43
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
43
neostigmine/glycopyrrolate + sugammadexMerckApproved
43
sugammadexMerckPhase 3
40
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
47
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
35
Sugammadex + NeostigmineMerckApproved
43
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
43
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
43
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium Bromide + Rocuronium BromideMerckApproved
43
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
22